Queensland Paediatric Cardiac Service, Queensland Children's Hospital, Brisbane, Australia; Children's Health Queensland Clinical Unit, School of Medicine, University of Queensland, Brisbane, Australia; Queensland Paediatric Cardiac Research, Children's Health Queensland, Brisbane, Australia.
School of Medicine, University of Queensland, Brisbane, Australia.
J Thorac Cardiovasc Surg. 2021 Nov;162(5):1313-1320. doi: 10.1016/j.jtcvs.2020.12.145. Epub 2021 Jan 23.
To evaluate the midterm results of pulmonary valve leaflet augmentation in transannular repair of tetralogy of Fallot (TOF).
From 2007 to 2019, 131 patients underwent a transannular repair with pulmonary leaflet augmentation for TOF (n = 120) and double outlet right ventricle with pulmonary stenosis (n = 11). Patch material was expanded polytetrafluoroethylene (n = 76), glutaraldehyde-treated autologous pericardium (n = 47) and bovine pericardium (n = 8).
Median age at repair was 8.9 months (interquartile range, 5.4-14.8). There was no operative mortality. Median follow-up was 6.25 years (interquartile range, 2.77-7.75). Freedom from severe pulmonary regurgitation (PR) was 85% (95% confidence interval [CI], 77%-90%) and 76% (95% CI, 66%-83%) at 1 and 5 years, respectively. Freedom from moderate or greater PR was 69% (95% CI, 60%-76%) and 30% (95% CI, 21%-39%) at 5 and 10 years, respectively. Three patients required pulmonary valve replacement for PR. Nine patients required pulmonary balloon valvuloplasty. Freedom from intervention for pulmonary valve stenosis was 98% (95% CI, 93%-99%) and 94% (95% CI, 87%-97%) at 1 and 5 years, respectively. One patient with severe PR had an indexed right ventricular volume >160 mL/m. Use of expanded polytetrafluoroethylene resulted in a greater freedom from moderate or greater PR (log-rank test P < .001; Cox regression hazard ratio, 0.40; 95% CI, 0.25-0.63; P < .001).
At midterm follow-up of transannular repair with pulmonary valve leaflet augmentation, severe PR occurs in less than 50% of patients. The expanded polytetrafluoroethylene patch performs better than pericardium.
评估法洛四联症(TOF)跨环修复中肺动脉瓣叶补片的中期结果。
2007 年至 2019 年,131 例患者接受了跨环修复术,其中 120 例为 TOF,11 例为右心室双出口伴肺动脉瓣狭窄。补片材料为膨化聚四氟乙烯(n=76)、戊二醛处理的自体心包(n=47)和牛心包(n=8)。
中位修复年龄为 8.9 个月(四分位间距,5.4-14.8)。无手术死亡。中位随访时间为 6.25 年(四分位间距,2.77-7.75)。重度肺动脉瓣反流(PR)无复发率为 85%(95%置信区间[CI],77%-90%)和 76%(95% CI,66%-83%),分别为 1 年和 5 年。中度或更严重的 PR 无复发率为 69%(95% CI,60%-76%)和 30%(95% CI,21%-39%),分别为 5 年和 10 年。3 例患者因 PR 行肺动脉瓣置换术。9 例患者行肺动脉瓣球囊扩张术。肺动脉瓣狭窄无干预的无复发率为 98%(95% CI,93%-99%)和 94%(95% CI,87%-97%),分别为 1 年和 5 年。1 例严重 PR 患者的右心室指数容积>160ml/m。膨化聚四氟乙烯的使用使中度或更严重的 PR 无复发率更高(对数秩检验 P<0.001;Cox 回归风险比,0.40;95% CI,0.25-0.63;P<0.001)。
在跨环修复伴肺动脉瓣叶补片的中期随访中,不到 50%的患者发生严重 PR。膨化聚四氟乙烯补片的效果优于心包。